

# Agenda – Y Pwyllgor Iechyd, Gofal Cymdeithasol a Chwaraeon

---

Lleoliad:	I gael rhagor o wybodaeth cysylltwch a:
<b>Fideo Gynadledda drwy Zoom</b>	<b>Sarah Beasley</b>
Dyddiad: Dydd Mercher, 18 Tachwedd 2020	Clerc y Pwyllgor 0300 200 6565
Amser: 09.00	<a href="mailto:Seneddlechyd@senedd.cymru">Seneddlechyd@senedd.cymru</a>

---

Yn unol â Rheol Sefydlog 34.19, mae'r Cadeirydd wedi penderfynu gwahardd y cyhoedd o gyfarfod y Pwyllgor at ddibenion diogelu iechyd y cyhoedd. Bydd y cyfarfod hwn yn cael ei ddarlledu'n fyw ar [www.senedd.tv](http://www.senedd.tv)

## Rhag-gyfarfod anffurfiol (09.00–09.30)

**1 Cyflwyniad, ymddiheuriadau, dirprwyon a datgan buddiannau**  
(09.30)

**2 COVID–19: Sesiwn dystiolaeth gyda'r Athro Robert West a'r Athro Susan Michie**

(09.30–10.30)

(Tudalennau 1 – 28)

Yr Athro Robert West, Athro mewn Seicoleg Iechyd – Coleg Prifysgol Llundain

Yr Athro Susan Michie, Athro Seicoleg Iechyd a Chyfarwyddwr y Ganolfan er

Newid Ymddygiad – Coleg Prifysgol Llundain

## Egwyl (10.30–10.45)

**3 COVID–19: Sesiwn dystiolaeth gyda'r Athro David Heymann a'r Athro Devi Sridhar**

(10.45–12.00)

(Tudalennau 29 – 31)

Yr Athro David Heymann, Athro Epidemioleg Clefydau Heintus – Ysgol

Hylendid a Meddygaeth Drofannol Llundain a Phennaeth y Ganolfan ar

Ddiogelwch Iechyd Byd-eang yn Chatham House, Llundain



Yr Athro Devi Sridhar, Athro a Chadeirydd Iechyd Cyhoeddus Byd-eang –  
Prifysgol Caeredin

#### **4 Papurau i'w nodi**

(12.00)

##### **4.1 Llythyr gan Gadeirydd y Pwyllgor Plant, Pobl Ifanc ac Addysg ynglŷn â Chyllideb Ddrafft Llywodraeth Cymru ar gyfer 2021–22**

(Tudalennau 32 – 36)

#### **5 Cynnig o dan Reol Sefydlog 17.42 (ix) i benderfynu gwahardd y cyhoedd o weddill y cyfarfod**

(12.00)

#### **6 COVID–19: Trafod y dystiolaeth**

(12.00–12.30)

Mae cyfyngiadau ar y ddogfen hon



## Living with the COVID-19 pandemic: act now with the tools we have

Published Online  
October 8, 2020  
[https://doi.org/10.1016/S0140-6736\(20\)32117-6](https://doi.org/10.1016/S0140-6736(20)32117-6)

The responses of countries to the COVID-19 pandemic have been disparate.<sup>1,2</sup> Many countries are reopening workplaces, schools, and social gatherings and striving to adapt their economies and resume international travel. Other countries are attempting to suppress transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by again restricting businesses, industries, and schools while hoping for future COVID-19 vaccines or treatments. The Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH), the independent advisory group to the WHO Health Emergencies Programme, has reviewed information from countries around the world and has concluded that the most sound approach on the basis of current understanding is to deploy long-term strategies with a focus on preventing amplification of transmission, protecting those most at risk of severe illness, and supporting research to better understand the virus, the disease, and people's responses to them.

Evidence suggests that children shed SARS-CoV-2 as do adults, mostly with non-severe clinical presentations.<sup>3</sup> But many characteristics of SARS-CoV-2 are not yet fully understood, such as the levels of immunity and the immune response, the full spectrum of disease and long-term sequelae, the possibility of re-infection,<sup>4,5</sup> and the potential of the virus to become endemic. Until more is known about the immune response to SARS-CoV-2, it is not possible to make sound predictions.

SARS-CoV-2 does not seem to behave epidemiologically like influenza virus and continues to resurge in clusters or outbreaks, not always in waves with rapid widespread community transmission.<sup>6</sup> With a more precise and epidemiologically based public health response involving active case finding, contact tracing, and strategic testing strategies, outbreaks caused by SARS-CoV-2 can be contained and community spread decreased to a more manageable level.<sup>7</sup> Some countries in Asia and Europe (eg, South Korea, Japan, Hong Kong, Singapore, Vietnam, and Germany)<sup>1,2</sup> have shown that this approach keeps transmission at sustainably lower and safer levels than in countries not following this approach, thus preventing surges of patients in health facilities and decreasing overall mortality.<sup>2</sup> This

approach is based on three principles: understanding, trust, and participation by all population groups; decreased transmission of SARS-CoV-2 using basic epidemiological and public health interventions; and acknowledging that any potential COVID-19 vaccines and treatments will only be part of the solution and that they will best perform in conjunction with a long-term overall public health strategy. The components of this epidemiologically based public health response to the COVID-19 pandemic (panel)<sup>8</sup> are familiar to public health specialists, but have been neglected or are inappropriately understood in some countries, both by leaders and the general public.

Alongside this comprehensive response, continued assessment is needed of how best to resume international travel. Most countries have focused on international travel as a risk for the (re)introduction of SARS-CoV-2 and use various risk-mitigation strategies (eg, PCR testing of international travellers and voluntary or mandatory isolation after arrival). Yet there is no optimum way to prevent importation of SARS-CoV-2, no matter how rigorously quarantine and testing are applied, because of the range in the SARS-CoV-2 incubation period (2–14 days),<sup>11</sup> the spectrum of disease (with subclinical and mild illness in many infected individuals), the fact that many travellers return to households with others who are not quarantined, and the number of days after infection to the time when PCR testing becomes positive. Other measures that could be equally or more effective include urging travellers to monitor their health and recommending they do not travel when ill; questioning travellers about their health status immediately before they travel; adhering to personal hygiene measures, physical distancing, and wearing masks in public when physical distancing is not possible; reporting illnesses to the destination country; and ensuring implementation of measures to provide safe travel environments. Introduction of digital smart tools might complement these measures and their evaluation should be continued.

Many countries consider that travel is safer from locations with low circulation of SARS-CoV-2 and strong capacities for outbreak containment, and they

are keen to obtain credible information about the infection and transmission status of other countries. Available WHO case reports are, however, based on laboratory-confirmed SARS-CoV-2 infections and since testing strategies vary by country<sup>7</sup> they are not an accurate indication of true transmission rates. Identification and use of more meaningful indicators of infection and transmission status are urgently required.

COVID-19 vaccines, therapeutics, and diagnostics are important for the pandemic response, and if any of the COVID-19 vaccine candidates are shown to be safe and effective, they will probably be deployed before full approval through emergency use authorisations or other strategies. Strategies must be developed to ensure equitable access through the COVAX pillar of the Access to COVID-19 Tools (ACT) Accelerator<sup>12</sup> and other mechanisms. In terms of treatments, use of glucocorticoids for critically ill patients is now best practice on the basis of evidence from clinical trials.<sup>13</sup> Other therapeutics, including antivirals (nucleoside analogues and antibody preparations) and immunomodulators, continue to be investigated.<sup>14</sup> Multiple diagnostic tests for nucleic acid, antigen, and antibody are being evaluated, including by a partnership between WHO and the Foundation for Innovative New Diagnostics (FIND).<sup>15</sup> As results of this research become available, countries will be able to make decisions about which tests meet their own standards and fit with their testing strategies. One example is the announcement by WHO, FIND, and The Global Fund to Fight AIDS, Tuberculosis and Malaria on the provision of externally validated, point-of-care rapid antigen detection diagnostic tests for SARS-CoV-2.<sup>16</sup> As other diagnostic tests are externally validated, they must be made widely available through the ACT Accelerator and other access mechanisms. Despite the urgency of identifying effective therapeutics and vaccines for COVID-19, the rules of science and the ethics of clinical research do not change in the setting of a pandemic. The most effective way to develop vaccines and therapeutics is through trials with robust safety and efficacy endpoints.

With current knowledge, even in the absence of COVID-19 vaccines or treatments and comprehensive knowledge of the immune response to SARS-CoV-2, countries can navigate pathways to reduced transmission, decreased severe illness and mortality, and less economic disruption in the short and longer term.

**Panel: Checklist of the basic components of an epidemiologically sound public health response to COVID-19 pandemic**

- ✓ **Rapidly detect people with infection, outbreaks, and sites of increased transmission**  
Strengthen surveillance of influenza-like illness<sup>9</sup> and acute respiratory tract infections and/or establish detection systems in health and other sectors, including schools, the homes of schoolchildren, and workplaces
- ✓ **Isolate and manage people infected with SARS-CoV-2**  
Individuals who test positive for SARS-CoV-2 need to be isolated and managed at an appropriate level of care with best practices that incorporate evolving evidence
- ✓ **Investigate outbreaks**  
Retrospective contact tracing and diagnostic testing, and/or serological surveys<sup>10</sup> are needed to investigate outbreaks and understand where transmission is occurring
- ✓ **Decrease community transmission**  
Prospective contact tracing and self-quarantine of contacts must be undertaken, with the use of testing in a way that ensures that those contacts who develop signs and symptoms of COVID-19 can be properly managed
- ✓ **Strengthen control measures**  
Ensure individuals, communities, and organisations are fully engaged in control activities (eg, physical distancing, wearing masks, and handwashing and cough and sneeze etiquette)
- ✓ **Ensure that testing is strategic**  
Use highly sensitive and specific nucleic acid, antigen, and antibody tests linked to surveillance and contact tracing, patient diagnosis, and management
- ✓ **Protect the health and social care system**  
Ensure that health facilities can accommodate the current disease burden and any disease occurring from future resurgence by protecting health workers and strengthening infection prevention and control practices; understanding the characteristics of high-risk groups and increasing their protection, especially in institutions such as care homes where they may live; and monitoring the health-care system to plan for and secure additional capacity if needs arise
- ✓ **Continue mitigation of general risks**  
Prevent or de-risk large public gatherings and events
- ✓ **Involve the business and private sectors**  
Engage with private sector in innovative ways to ensure a safe and productive workforce
- ✓ **Apply short-term preventive and mitigation measures**  
Use these short-term measures, such as time-limited closures and restrictions where transmission is occurring, until transmission has been reduced or eliminated
- ✓ **Conduct, fund, and support research**  
Research is crucial to better understand the characteristics of SARS-CoV-2, including the course of infection and the immune response; establish cohort studies to understand the extent of sequelae; and conduct qualitative studies to better understand and strengthen people's response to COVID-19; at the same time, continued clinical research on vaccines, therapeutics, and diagnostics is also required

Despite geopolitical tensions, information contributing to greater understanding of COVID-19 continues to be shared within the scientific community and with WHO. International travel is increasing, economic

## Comment

and education sectors are reopening, and countries are benefiting from the experiences of others as they continue to live with the COVID-19 pandemic and develop more effective control strategies.

We are all members of the WHO Strategic and Technical Advisory Group for Infectious Hazards and declare no competing interests.

*Juliet Bedford, Delia Enria, Johan Giesecke,  
\*David L Heymann, Chikwe Ihekweazu, Gary Kobinger,  
H Clifford Lane, Ziad A Memish, Myoung-don Oh,  
Amadou Alpha Sall, Kumnuan Ungchusak, Lothar H Wieler,  
for the WHO Strategic and Technical Advisory Group for  
Infectious Hazards*

david.heyman@lshtm.ac.uk

Anthologica, Oxfordshire, UK (JB); Instituto Nacional de Enfermedades Virales Humanas "Julio Maiztegui" and CCWHO-OPS on Viral Haemorrhagic Fevers and Arboviruses, Buenos Aires, Argentina (DE); Karolinska Institute, Stockholm, Sweden (JG); Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK (DLH); Nigeria Centre for Disease Control, Abuja, Nigeria (CI); Infectious Disease Research Centre, Université Laval, Faculty of Medicine, Québec City, QC, Canada (GK); National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA (HCL); Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh, Saudi Arabia (ZAM); JW Lee Center for Global Medicine, SNU College of Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea (M-dO); Institut Pasteur de Dakar, Dakar, Senegal (AAS); Ministry of Health, Department of Diseases Control, Bangkok, Thailand (KU); and Robert Koch Institute, Berlin, Germany (LHW)

- 1 WHO. WHO coronavirus disease (COVID-19) dashboard. 2020. <https://covid19.who.int/> (accessed Oct 1, 2020).
- 2 WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/> (accessed Oct 1, 2020).
- 3 Usher Network for COVID-19 Evidence Reviews (UNCOVER). Summary: what is the evidence for transmission of COVID-19 by children [or in schools]? July, 2020. [https://www.ed.ac.uk/files/atoms/files/uncover\\_children\\_transmission\\_of\\_sars-cov-2\\_update\\_4\\_final.pdf](https://www.ed.ac.uk/files/atoms/files/uncover_children_transmission_of_sars-cov-2_update_4_final.pdf) (accessed Oct 1, 2020).

- 4 To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis* 2020; published online Aug 25. <https://doi.org/10.1093/cid/ciaa1275>.
- 5 Tillett R, Sevinsky J, Hartley P, et al. Genomic evidence for a case of reinfection with SARS-CoV-2. *SSRN* 2020; published online Aug 25. <http://dx.doi.org/10.2139/ssrn.3680955> (preprint).
- 6 Furuse Y, Sando E, Tsuchiya N, et al. Clusters of coronavirus disease in communities, Japan, January–April 2020. *Emerg Infect Dis* 2020; **26**: 2176–79.
- 7 WHO. WHO COVID-19 strategic preparedness and response plan. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans> (accessed Oct 1, 2020).
- 8 WHO. Country and technical guidance—coronavirus disease (COVID-19). 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance> (accessed Oct 1, 2020).
- 9 WHO. Operational considerations for COVID-19 surveillance using GISRS: interim guidance. March 26, 2020. <https://www.who.int/publications/i/item/operational-considerations-for-covid-19-surveillance-using-gisrs-interim-guidance> (accessed Oct 1, 2020).
- 10 WHO. Coronavirus disease (COVID-19) technical guidance: the Unity Studies: early investigation protocols. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations> (accessed Oct 1, 2020).
- 11 McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. *BMJ Open* 2020; **10**: e039652.
- 12 WHO. COVAX. COVAX, the Act-Accelerator vaccine pillar. 2020. <https://www.who.int/publications/m/item/covax-the-act-accelerator-vaccines-pillar> (accessed Oct 1, 2020).
- 13 WHO. Corticosteroids for COVID-19. Sept 2, 2020. <https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1> (accessed Oct 1, 2020).
- 14 WHO. WHO International clinical trials registry platform. 2020. <https://www.who.int/ictpr/en/> (accessed Oct 1, 2020).
- 15 WHO. Coronavirus disease (COVID-19) pandemic—Emergency Use Listing Procedure (EUL) open for in vitro diagnostics. 2020. [https://www.who.int/diagnostics\\_laboratory/EUL/en/](https://www.who.int/diagnostics_laboratory/EUL/en/) (accessed Oct 1, 2020).
- 16 WHO. Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries. Sept 28, 2020. <https://www.who.int/news-room/detail/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low--and-middle-income-countries> (accessed Oct 1, 2020).



## The opioid crisis and the 2020 US election: crossroads for a national epidemic

Published Online  
October 6, 2020  
[https://doi.org/10.1016/S0140-6736\(20\)32113-9](https://doi.org/10.1016/S0140-6736(20)32113-9)

Health care is a major point of differentiation in the upcoming US presidential elections. One priority area is the opioid crisis. In 2019, reported deaths from drug overdose in the USA reached an all-time high of almost 72 000, with opioids involved in more than two-thirds of the total deaths.<sup>1</sup> The COVID-19 pandemic has exacerbated an already difficult situation by reducing access to life-saving treatment, harm reduction, and recovery support services, while increased stress and isolation might increase the risk of addiction and substance use disorders (SUDs).<sup>2</sup> As of July, 2020, deaths from drug overdose in the USA rose by an estimated 13% in the first half of the

year compared with 2019, according to data compiled from several local and state governments. In some states, drug-related deaths climbed by over 30%.<sup>3</sup> The pandemic has also triggered an economic recession that threatens the survival of some addiction treatment centres,<sup>4</sup> and is expected to exacerbate social barriers such as housing instability, which can further hinder treatment of SUDs.<sup>5</sup> Against this backdrop, the presidential candidates propose divergent policy solutions to counter the opioid epidemic. There are three major differences.

First, the policy proposals differ in how they will treat addiction. Just one in five people with opioid use

Tudalen y pecyn 31

Senedd Cymru  
**Item 4.1**  
**Y Pwyllgor Plant, Pobl Ifanc ac Addysg**

Welsh Parliament

**Children, Young People and Education Committee**

Vaughan Gething AS, y Gweinidog Iechyd a Gwasanaethau Cymdeithasol

Julie Morgan AS, y Dirprwy Weinidog Iechyd a Gwasanaethau Cymdeithasol

Eluned Morgan AS, Y Gweinidog Iechyd Meddwl, Llesiant a'r Gymraeg

Dyddiad | Date: 06 Tachwedd 2020

Pwnc | Subject: **Cyllideb Ddrafft Llywodraeth Cymru ar gyfer 2021-22**

Annwyl Weinidogion,

Yn unol â'n harfer, rydym yn ysgrifennu cyn cyhoeddi Cyllideb Ddrafft Llywodraeth Cymru ar gyfer 2021-22 i ofyn am wybodaeth ysgrifenedig i lywio ein gwaith craffu.

Fel gyda'r blynyddoedd diwethaf, bydd ein dull yn seiliedig ar bedair egwyddor o ran craffu ariannol, sef: fforddiadwyedd, blaenoriaethu, gwerth am arian a phrosesau'r gyllideb. Byddwn hefyd yn gofyn am dystiolaeth gan y Gweinidog Addysg ar faterion sy'n berthnasol i'n cylch gwaith.

Nodwn fwriad Llywodraeth Cymru i gyhoeddi'r Gyllideb Ddrafft ar gyfer 2021-22 ar 21 Rhagfyr 2020, ar ôl i Lywodraeth y DU gyhoeddi y bydd ei Adolygiad o Wariant un flwyddyn yn digwydd ar 25 Tachwedd. Rydym ni yn bwriadu cynnal sesiynau tystiolaeth cyn gynted ag sy'n bosibl ar ôl toriad y Nadolig - bydd y Clerc mewn cysylltiad i nodi'r manylion terfynol ar ôl i'r Pwyllgor Busnes gytuno ar Amserlen y Senedd ar gyfer 2021. Byddem yn ddiolchgar o dderbyn y wybodaeth fanwl a amlinellir yn yr Atodiad i'r llythyr hwn o leiaf ddwy wythnos waith cyn y dyddiad y bydd y cyfarfod hwnnw yn cael ei gynnal.

O ystyried y diddordeb cyffredin ar draws y pwyllgorau mewn rhai o'r meysydd a restrir yn yr Atodiad i'r llythyr hwn, rwy'n rhoi copi o'r llythyr i Dr Dai Lloyd AS, Cadeirydd y Pwyllgor Iechyd, Gofal Cymdeithasol a Chwaraeon.

Yn gywir,



**Lynne Neagle AS**  
**Cadeirydd**

Copi at: Dr Dai Lloyd AS, Cadeirydd y Pwyllgor Iechyd, Gofal Cymdeithasol a Chwaraeon  
Croesewir gohebiaeth yn y Gymraeg a'r Saesneg/We welcome correspondence in both English and Welsh



**Senedd Cymru**  
Bae Caerdydd, Caerdydd, CF99 1SN

 SeneddPPIA@senedd.cymru

 0300 200 6565

**Welsh Parliament**  
Cardiff Bay, Cardiff, CF99 1SN

 SeneddCYPE@senedd.wales

 0300 200 6565

## ATODIAD – Cais am wybodaeth ysgrifenedig cyn craffu ar y Gyllideb Ddrafft

Byddai'r Pwyllgor yn croesawu ymateb i bob un o'r pwyntiau isod:

### 1. Tryloywder o ran y gwariant ar blant

Fel mewn blynyddoedd blaenorol, rydym yn pwysleisio pwysigrwydd cyflwyno'r Gyllideb Ddrafft yn dryloyw er mwyn galluogi gwaith craffu llawn a thrylwyr. Gofynnwn am esboniad naratif tryloyw (a darlunio rhifol) ar y canlynol:

- gostyngiadau/dileu neu gynyddu/ychwanegu o ran meysydd penodol o'r Gyllideb Ddrafft o'u cymharu â'r blynyddoedd ariannol blaenorol (e.e. lleihau grantiau neu grantiau'n peidio â bodoli'n gyfan gwbl/cyflwyno grantiau neu eu cynyddu);
- pa gyfran y mae unrhyw newidiadau i'r swm cyffredinol a ddyrannwyd yn flaenorol yn ei chynrychioli; a
- lle yn union mae'r newid hwn yn cael ei wneud yn y Gyllideb Ddrafft, a ph'un a fydd arian yn cael ei ddychwelyd i/ei gymryd o gronfeydd wrth gefn canolog neu ei ddyrannu i/o linellau cyllideb eraill.
- gwybodaeth am yr effaith y mae COVID-19 wedi'i chael ar ddyraniadau.

Gofynnwn ymhellach i Weinidogion sicrhau bod adnoddau sy'n ymwneud â phlant a phobl ifanc yn cael eu cyflwyno'n glir fel y gallwn nodi'r adnoddau a neilltuwyd, asesu i ba raddau y maent yn cael eu blaenoriaethu, a deall sut y byddant yn sicrhau gwerth am arian.

### 2. Esboniad ar ddyraniadau

- Dadansoddiad o ddyraniadau'r Prif Grŵp Gwariant (MEG) Iechyd a Gwasanaethau Cymdeithasol ar gyfer 2021-22 fel sy'n berthnasol i blant a phobl ifanc, yn ôl Maes y Rhaglen Wariant (SPA), Cam Gweithredu a'r Llinell Wariant yn y Gyllideb, gan gynnwys dadansoddiad o'r newidiadau sylweddol ers Cyllideb Atodol Gyntaf 2019-20 ac esboniad arnynt.
- Dyraniadau MEG Iechyd a Gwasanaethau Cymdeithasol Dangosol ar gyfer 2022-23 fel sy'n berthnasol i blant a phobl ifanc, os ydynt ar gael.
- Esboniad ar bob un o'r camau gweithredu o fewn y MEG Iechyd a Gwasanaethau Cymdeithasol fel sy'n berthnasol i blant a phobl ifanc, gan gynnwys dadansoddiad o'r newidiadau rhwng Cyllideb Ddrafft 2021-22 a Chyllideb Atodol Gyntaf 2020-21 ac esboniad arnynt.



### 3. Effaith gwariant ar ddatblygu hawliau plant o dan Fesur Hawliau Plant a Phobl Ifanc (Cymru)

O ran Cyllideb Ddrafft Llywodraeth Cymru ar gyfer 2021-22 ar draws pob portffolio, mae'r Pwyllgor:

- yn ailadrodd ei gais i Asesiad o'r Effaith ar Hawliau Plant (CRIA) gael ei gynnal ar gyfer y Gyllideb Ddrafft fel mater o drefn.
- yn gofyn am gopi o'r Asesiad o'r Effaith ar Hawliau Plant cyffredinol a wnaed gan Lywodraeth Cymru i lywio'r dyraniadau yn y Gyllideb Ddrafft ar gyfer 2021-22. Os na chynhaliwyd Asesiad o'r fath penodol, y rhesymau dros hyn a chopi o unrhyw asesiad effaith integredig arall.

O ran **MEG Iechyd a Gwasanaethau Cymdeithasol**, byddai'r Pwyllgor yn ddiolchgar o dderbyn gwybodaeth am y canlynol:

- sut mae Deddf Llesiant Cenedlaethau'r Dyfodol (Cymru) 2015 wedi dylanwadu ar ddyraniadau i linellau'r gyllideb o fewn y MEG; a
- manylion a/neu enghreifftiau o unrhyw newidiadau a wnaed i ddyraniadau o fewn y MEG Iechyd a Gwasanaethau Cymdeithasol yn dilyn ystyriaethau o ran hawliau plant, cydraddoldeb, cynaliadwyedd, y Gymraeg, neu Lesiant Cenedlaethau'r Dyfodol.

### 4. Dyraniadau o ran polisi a deddfwriaeth

Mae'r Pwyllgor yn gofyn am ddiweddariad ar ddyraniadau o fewn MEG Iechyd a Gwasanaethau Cymdeithasol y Gyllideb Ddrafft ar gyfer 2021-22 yn y meysydd canlynol sydd o ddiddordeb i'r Pwyllgor, gan gynnwys:

- **Costau deddfwriaeth:** Gwariant wedi'i gynllunio ar weithredu Deddf Plant (Diddymu Amddiffyniad Cosb Resymol) (Cymru) yn y cyfnod cyn iddi ddod i rym.
- **Tlodi plant:** Dyraniadau i leihau tlodi ac i atal rhagor o blant rhag byw mewn cartrefi incwm isel yng nghyd-destun y sefyllfa economaidd bresennol sy'n deillio o'r pandemig COVID-19.
- **Dechrau'n Deg:** Cyllid refeniw a chyllid cyfalaf; y sefyllfa ddiweddaraf ar yr arian allgymorth. Gwerth am arian a chynnydd wrth asesu canlyniadau dyraniadau a gwariant.
- **Rhaglen Teuluoedd yn Gyntaf**
- **Gofal Plant:** gan gynnwys y cynnig gofal plant ac unrhyw ddyraniadau ychwanegol sy'n codi o'r adolygiad o hawl rhieni, esboniad ar ddyraniadau ychwanegol yn yr ail Gyllideb Atodol fis Hydref 2020; Rhieni, Gofal Plant a Chyflogaeth (PaCE); datblygu'r gweithlu; cyllid gofal plant arall.
- **Gwasanaethau Gwybodaeth i Deuluoedd**
- **Cefnogaeth rhianta,** gan gynnwys unrhyw ddiweddariadau ar ddyraniadau sy'n gysylltiedig â gweithredu Deddf Plant (Diddymu Amddiffyniad Cosb Resymol) (Cymru).

- **Gwasanaethau diogelu**
- **Plant sy'n derbyn gofal:** gan gynnwys gwasanaethau maethu; gwasanaethau Ar Ffiniau Gofal / gwasanaethau i atal plant rhag derbyn gofal; Gadael cymorth gofal. Gwerth am arian a chynnydd wrth olrhain canlyniadau mewn perthynas â gwariant.
- **Mabwysiadu:** gan gynnwys cymorth ar ôl mabwysiadu.
- **Gwasanaethau eiriolaeth:** gan gynnwys dyraniadau i gefnogi'r Dull Cenedlaethol
- **Y Gwasanaeth Cyngori a Chynorthwyo Llys i Blant a Theuluoedd**
- **Hawliau plant a phobl ifanc,** gan gynnwys dyraniadau i Cymru Ifanc, a gwerth am arian. Dyraniadau i weithredu argymhelliad adroddiad y Pwyllgor ar Hawliau Plant.
- **Swyddfa Comisiynydd Plant Cymru**
- **Polisi a gwasanaethau chwarae:** gan gynnwys Chwarae Cymru a chynllun Gwaith Chwarae i atal llwgu yn ystod y gwyliau.
- **Gwasanaethau plant anabl**
- **Gordewdra ymhlith plant:** Gwybodaeth a ddsbarthwyd i weithredu'r cynllun 'Pwysau Iach: Cymru Iach'.
- **Gwasanaethau newyddenedigol:** Y dyraniadau i gyflawni'r adolygiad diweddaraf o Safonau Newyddenedigol Cymru Gyfan; blaenoriaethau Llywodraeth Cymru ar gyfer gwasanaethau newyddenedigol ar gyfer y 12 mis nesaf; a sut bydd dyraniad y gyllideb ar gyfer 2021-22 yn helpu i ysgogi gwelliant o ran perfformiad.
- **Iechyd Meddwl Amenedigol:** gwybodaeth am:
  - effaith COVID-19 ar y gwasanaethau iechyd meddwl amenedigol a'r dyraniadau i fynd i'r afael â hynny;
  - dyraniadau i gefnogi datblygiad pellach gwasanaethau ar draws pob ardal yng Nghymru, gan gynnwys mewn perthynas â safonau ansawdd, llwybrau gofal a darpariaeth i gleifion mewnol [Yn benodol: lefel y buddsoddiad i sefydlu uned mamau a babanod amenedigol arbenigol yng Nghymru; a dadansoddiad o'r cyllid fesul Bwrdd Iechyd ar gyfer gwasanaethau cymorth iechyd meddwl amenedigol cymunedol, gan gynnwys esboniad ar yr amcanion ar gyfer y cyllid hwn, a pha drefniadau y mae Llywodraeth Cymru wedi'u sefydlu i fonitro gwariant ac i werthuso ei effaith].

## 5. Iechyd Meddwl a Lles Emosiynol Plant a Phobl Ifanc

Fel ffocws allweddol gwaith craffu'r Pwyllgor yn ystod y Pumed Senedd hon, byddem yn croesawu cael:

- Esboniad manwl mewn cysylltiad ag iechyd meddwl a lles emosiynol plant a phobl ifanc, gan gynnwys goblygiadau ariannol ymateb Llywodraeth Cymru i'r argymhellion a nodwyd yn yr adroddiad Cadernid Meddwl gan y Pwyllgor a'r argymhellion dilynol ar gyfer y MEG Iechyd a Gwasanaethau Cymdeithasol yn 2021-22.
- Gwybodaeth am ddyraniadau o ran iechyd meddwl a lles emosiynol plant a phobl ifanc yn 2021-22 a lle y gellir eu canfod yn y MEG Iechyd a Gwasanaethau Cymdeithasol h.y. Manylion y Meysydd Rhaglen Gwariant, y Camau Gweithredu a'r Llinellau Gwariant yn y Gyllideb (BEL) perthnasol.

**Byddem yn croesawu cael rhagor o fanylion am:**

- Cyllid ar gyfer cyflawni blaenoriaethau ar gyfer iechyd meddwl a lles emosiynol plant a phobl ifanc fel y nodir yn y Cynllun Cyflawni, sef Law yn Llaw at Iechyd Meddwl diwygiedig.
- Manylion y cyllid i liniaru effeithiau COVID-19 ar iechyd meddwl a lles plant a phobl ifanc, gan gynnwys sut y bydd hwn yn mynd i'r afael â'r effaith anghymesur ar rai grwpiau (gan gynnwys, er enghraifft, y rhai ag afiechyd meddwl eisoes, plant sy'n derbyn gofal a phlant sy'n agored i niwed, a grwpiau incwm isel).
- Sut y bydd y Gyllideb Ddrafft hon yn cefnogi dull 'system gyfan', traws-Lywodraethol a thraws-sector o ran iechyd meddwl a llesiant plant a phobl ifanc, gan gynnwys ffocws ar atal / ymyrraeth gynnar a meithrin gwytnwch.
- Cyllid i gefnogi datblygiad a chynaliadwyedd y gweithlu gofal iechyd plant a phobl ifanc, gan gynnwys cyfeiriad penodol at y gweithlu iechyd meddwl plant a phobl ifanc.
- Gwybodaeth am y gronfa gwella'r gwasanaeth iechyd meddwl, gwerth £7 miliwn, gan gynnwys (mewn perthynas â phlant a phobl ifanc) manylion am sut mae'r cyllid hwn yn cael ei ddefnyddio gan fyrdau iechyd yn 2020-21, a'r amcanion / blaenoriaethau o ran y cyllid hwn ar gyfer 2021- 22.